Expansion Opportunity PharmaLogic is rapidly expanding its radiopharmaceutical manufacturing footprint across the United States and internationally, including new facilities in Idaho Falls, Atlanta, Los Angeles, Cincinnati, the Bronx, Salt Lake City, and Georgia. This presents a direct opportunity to engage with their expanded capacity plans, offering scalable CDMO services, supply chain optimization, and co-development partnerships for clinical and commercial radiopharmaceutical programs.

Therapeutics Leadership As the world’s only cGMP-compliant CDMO manufacturing and distributing a commercial radiopharmaceutical therapeutic across 30+ countries, PharmaLogic has strong traction in regulated, global markets. This creates sales potential for strategic development partnerships, technology licensing, and compliance-ready manufacturing solutions tailored to cross-border distribution and pharmacovigilance support.

Key Partnerships Recent collaboration announcements with Ratio Therapeutics and the emphasis on clinical development and commercialization readiness indicate a readiness to co-develop and scale radiopharmaceuticals. Target partnership discussions around joint development agreements, early-phase manufacturing, and scale-up services for novel radiopharmaceutical assets.

Diagnostics Growth PharmaLogic is expanding diagnostics broadly in oncology, cardiology, and Alzheimer’s disease, leveraging advanced technologies. This signals opportunities to offer end-to-end radiopharmacy services, including supply chain reliability for diagnostic tracers, regulatory filings support, and data analytics integration to optimize patient access and utilization.

Infrastructure Investment The substantial capital deployment, including a $250M PET facility in Atlanta and multi-site network growth, suggests a customer base with high service demand and long-term capacity commitments. Position services around facility readiness for scale, long-term supply agreements, and value-based manufacturing options that align with customer timelines and regulatory milestones.